2 Human Umbilical Cord Autoantibodies (Huc-Ab). An Ideal Screening Test for Coeliac Disease (Cd)

Sulkanen, Satu; Marttinen, A.; Hällström, O; Laurila, Kaija; Halttunen, Tuula; Mäki, Markku

doi:10.1097/00005176-199505000-00013

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AGAs, gamma/delta T cells, or mucosal IgA deposits have not yet solved this problem (15,27‐31). Establishment of the proper diagnostic value of the so‐called antireticulin antibodies, EmA, JeA, and anti‐umbilical cord antibodies (32,33) represents a multifaceted problem caused by different substrate‐ and method‐related sensitivities and specificities (34) of supposedly the same autoantibody system (20,35‐37). It seems that the use of primate gastrointestinal substrates (20,36) and the degree of local experience with a given method (34) correlate the best with comparable results.…”

Section: Discussionmentioning

confidence: 99%

Prospective Significance of Antiendomysium Antibody Positivity in Subsequently Verified Celiac Disease

Korponay‐Szabó,

Kovács,

Lörincz

et al. 1997

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Background:In order to assess their long‐term predictability for the diagnosis of celiac disease, antiendomysium antibody results were compared with the outcome of the Interlaken diagnostic process.Methods:Prospective gluten challenge was performed in 153 children with previously diagnosed flat small‐intestine mucosa. In 90 patients (Group A), endomysium antibodies were initially positive, in seven (Group B) they were negative, and 56 patients (Group C) had no initial serological results. In IgA‐deficient persons, IgG antibodies were also assayed, both by the immunofluorescent method.Results:Histological relapse rates were 100% (90/90), 14.3% (1/7), and 76.8% (43/56), p < 0.001, in Groups A, B, and C, respectively. Each patient with relapse also exhibited endomysium antibody positivity during the challenge. Patients in whom celiac disease could be finally ruled out remained consistently endomysium‐antibody negative. The celiac disease patient in Group B had severe secondary immunoglobulin deficiency at entry, which explained the initial negativity. Diagnosis based on antiendomysium antibody positivity and flat mucosa gave a higher applicability (92.8 vs. 50.3%) and reliability (relapse rate 100 vs. 89.6%) than the 1990 European Society of Paediatric Gastroenterology and Nutrition (ESPGAN) criteria among these patients.Conclusions:Endomysium antibody positivity at presentation has been found to be as useful as gluten challenge in the diagnosis of celiac disease, even in patients under the age of 2 years. Challenge is still advisable in patients with a flat small intestinal mucosa when antiendomysium antibody results are negative or have not been done, as among these patients significantly lower relapse rates were found.

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective Significance of Antiendomysium Antibody Positivity in Subsequently Verified Celiac Disease

Korponay‐Szabó,

Kovács,

Lörincz

et al. 1997

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

Anticorps anti-endomysium, anti-réticuline et anti-gliadine, intérêt dans le diagnostic de la maladie cœliaque chez l'enfant

Ghedira

Sghiri

Ayadi³

et al. 2001

Pathologie Biologie

View full text Add to dashboard Cite

Clinical Aspects of Coeliac Disease in Children with Insulin-Dependent Diabetes Mellitus

Lorini

Scaramuzza

Vitali

et al. 1996

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

Coeliac disease (CD) is heterogeneous in its clinical presentation and pathological expression. Silent, latent and potential forms represent the submerged part of the so-called "coeliac iceberg". The association of insulin-dependent diabetes mellitus (IDDM) and CD has been widely reported. For the screening of CD in diabetic patients, anti-reticulin R1 (ARA-R1) and anti-endomysium (AEA) antibodies are more reliable markers than anti-gliadin (AGA) antibodies. Recent studies have reported an increased prevalence of CD in children with IDDM. In our experience intestinal biopsy confirmed a diagnosis of CD in 6 out of 172 diabetic patients, with a prevalence of 3.5%. Only occasionally does CD precede the onset of IDDM; more often CD is diagnosed shortly or sometimes years after the onset of diabetes. Typical gastrointestinal complaints of CD (such as diarrhoea, abdominal distension) are rare in IDDM patients, while atypical isolated signs or symptoms of CD are more common, in particular sideropenic anemia, short stature, delayed puberty, epilepsy, hypertransaminasemia, dyspeptic symptoms, herpetiform dermatitis, and recurrent aphthous stomatitis. It is recommended that all diabetic children, even those asymptomatic, should be screened yearly for CD, using a combination of AGA plus ARA-R1 and AEA.

show abstract

2 Human Umbilical Cord Autoantibodies (Huc-Ab). An Ideal Screening Test for Coeliac Disease (Cd)

Cited by 3 publications

References 0 publications

Prospective Significance of Antiendomysium Antibody Positivity in Subsequently Verified Celiac Disease

Prospective Significance of Antiendomysium Antibody Positivity in Subsequently Verified Celiac Disease

Anticorps anti-endomysium, anti-réticuline et anti-gliadine, intérêt dans le diagnostic de la maladie cœliaque chez l'enfant

Clinical Aspects of Coeliac Disease in Children with Insulin-Dependent Diabetes Mellitus

Contact Info

Product

Resources

About